Innovation, the gene and development origin of Talsy,
driving us to make breakthroughs to make life shine
Tasly Group, founded in 1994, is a high-tech enterprise group. Looking forward to going globalization, we focus on Great Health industry with bio-pharmaceutical as the core and biomedical engineering as the coordination, while developing health care industry and medical rehabilitation, health maintenance and management services as two added wings.
Adhering to "Pursue the unity of man and nature, and improve people’s life quality" as our philosophy, we aim to share the joy of health with all human-being. We have now established newly brand value proposition “Thrive, with love” with the vision to jointly create a symbiotic & connectivity global life health value ecology so as to make continuous contribution to build Healthy China and promote development of human health industry.
We are dedicated to exploring the digital code of life medicine. Adhering to the concept of "patient-centered", we pay close attention to the evolution of disease spectrum and focus on the important therapeutic fields such as cardio-cerebrovascular, digestion and metabolism, tumor immunity and neuroscience that maintain the healthy life experience of human beings to make precise innovation.We have also began to explore emerging businesses such as cell therapy, Internet chronic disease + digital therapy, T-type industry and integrated medicine and the establishment of a new health management model integrating "prevention, treatment, management and control". We aim to provide personalized comprehensive integrated medical solutions for every patient and family, meet the diversified needs of individual life, optimize life experience and improve their life quality.
Guided by the national modernization and internationalization strategy of TCM, Compound Danshen Dripping Pill, the group's flagship product, has become the world's first compound Chinese medicine to carry out the global multi-center, large-sample, randomized double-blind Phase Ⅲ clinical trial conducted by US FDA. We have successfully achieved strategic cooperation with Arbor Company of the United States and created a precedent for collaborative development and promotion of compound Chinese medicine with overseas pharmaceutical companies.It has led other Chinese medicine products to "go global", opened up a new path of modern Chinese medicine internationalization, and built a new bridge of scientific research and mutual learning between China and the West.
Adhering to the development orientation of "advocate of great-health concept, creator of great-health products, designer of great-health management plan and practitioner of great-health culture", based on pharmaceutical technology and standards and users' demand for healthy life of high quality, we have built a modern liquor industry system with "Guotai" as the brand in Maotai Town, Guizhou Province, The company has built biological Pu 'er tea with the brand of Deepure in Pu 'er, Yunnan province, and a healthy drinking water industry system with the brand of "C-cell Vitality" in Changbai Mountain, Jilin Province. We have also steadily promoted the industrial system construction of medical rehabilitation, health preservation and health management, and is committed to protecting the health of the whole life cycle.
Adhering to the principle of "industry and capital as the core" and the coordinated development of "industry and capital", through 4D (Diagnosis, Drug, Device and Digital) investment linkage, we have built a great-health asset portfolio so as to rapidly improve the innovation and upgrading capacity of the industrial entity. We are committed to developing Tasly Capital into an asset management platform for consumers, entrepreneurs and investors in the great-health industry.
In the future, we will speed up the strategy of "two transformation and one upgrading" and apply modern scientific technologies and platform such as artificial intelligence and big data to transform to an innovative and intelligent-service enterprise, to upgrade from "products manufacturing as the core" to "intelligent manufacturing with products clustering and industry systemaltization", to promote high-tech, intellectual, high-end development and keep on the development to become a world-famous brand in health industry with bio-pharmaceutical as the core. By actively integrating global resources , we strive to make more and more innovations to create a great-health industry ecology throughout the whole life cycle so as to enable every family enjoy the joy of health and every life shine.
Innovation, running through the whole process of our establishment, development, transformation and upgrading, is the gene of Tasly and the origin of power to constantly drive us to break barriers, coruscating strong vitality and meeting future challenges.
Layout of the world's leading stem cell industry chain
Integration of Chinese and Western medicine innovation
Tianshili Pharmaceutical Company was established
Compound Danshen Dripping Pill was approved by the National New Drug Certificate
Compound Danshen Dripping Pill was approved by FDA IND
Built Guotai Liquor Company after acquisition of a time-honored brewing enterprise in Moutai Town
Tasly (600535) was listed in Shanghai Stock Exchange
Tasly Pharma. (US) was established
Compound Danshen Dripping Pill passed FDAⅡ clinical trial
Tasly Huai 'an Biomedical Industrial Park started construction
The results of "Recombinant Human Prourokinase for Injection", a national classⅠ bio-thrombolytic drug, were released
Guotai Winery was established in Renhuai Famous Wine Industrial Park
Tasly Deepure Biological Tea Valley was completed
Jilin Tasly Mineral Water Co.,Ltd launched into production.
State-local JoinEngineering Laboratory and State Key Laboratory of Core Technology in Innovative Chinese Medicine were approved
Compound Danshen Dripping Pill passed FDAⅢ clinical trial
Signed T89 R&D and marketing cooperation with Arbor Company in the United States
Be the first to complete the layout of the whole stem cell industry chain in China
The clinical phaseⅡtrial of Compound Danshen Dripping Pill on prevention and treatment of acute altitude syndrome was completed
Set up an International TCM Sharing Platform and carry out international academic exchanges on jointly fight of COVID-19
Tasly Holding Group awarded as National Advanced Collective in Poverty Alleviation
Tasly Great Health Industry Investment Group listed in Top 500 Chinese Manufacturing Enterprises in 2021
Tasly Great Health Industry Investment Group listed in Top 500 Private Enterprises in China in 2021
Tasili Pharmaceutical Group won the honorary title of National Youth Civilization
Tasly Pharma. Group was listed in the "Top100 List of Chinese Traditional Medicine Enterprises in 2019"
Tasly Pharma. Group was listed in Top 100 in Science and Technology Innovation
Tasly Holding Group was listed in China's Top 500 Manufacturers in 2020
Tasly Holding Group won the Annual Poverty Alleviation Award of 15th People's Corporate Social Responsibility Award
Tasly Holding Group won the title of "Backbone Enterprise of Pharmaceutical Industry in 70 Years since the Founding of New China"
Tasly Pharma. Group was selected as one of the Top 100 Innovative Pharmaceutical Enterprises in China
Tasly Holding Group was listed in the "2019 Top 500 Chinese Private Enterprises" ranking 290th and “2019 China's Top 500 Private Enterprises in Manufacturing" ranking 168thTasly Holding Group won the "National Public Welfare Contribution Award"
Tasly Holding Group was honored as "China's Industrial Model Enterprise"
Tasly Holding Group was awarded the "Advanced Private Enterprise targeted Poverty
Alleviation" of "Ten thousand Enterprises helping Ten Thousand Villages"
Tasly pharmaceutical group entered "TOP5 of China TCM r&d strength list 2018"
Tasly Holding Group was listed in the "2018 China's Top 500 Manufacturing Enterprises", ranking 259th
Tasly Holding Group won the "Originality quality brand" award
Shanghai Tasly Pharmaceutical Co., LTD. "Recombinant Human Urokinase for Injection" was awarded "The Most Innovative Drug with Clinical Value"
Tasly Holding Group won the award of "Top 10 Industrial Tourism Brand"
Tasly was listed as one of the Top 100 Chinese Brands in 2017
Tasly Compound Danshen Dripping Pill’s brand value exceeding 5 billion RMB, ranked in "2016 Chinese Drug Brand Value List"Tasly (600535) ranked in the "2017 China Listed Company Brand Value List (Top50 Private Enterprises)"
Tasly Pharmaceutical Group was awarded the title of "Intelligent Manufacturing Pilot Demonstration" by the Ministry of Industry and Information Technology
Tasly (600535) was awarded the title of "Top 100 Listed Companies by Value in China's main board"
Tasly Holding Group ranks No. 264 in "2016 China's Top 500 Manufacturers List"
Tasly Pharmaceutical Group was selected as one of the Top 20 Most Competitive Listed Pharmaceutical Companies in China.